What This Bill Does · Plain English
GovGreed Synthesis · AI extraction
This bill places a $50 million cap on the total funds that can be made available for the 'Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act' for fiscal year 2024. It overrides any other laws that might authorize or provide more money for this specific account.
Carveouts & Earmarks · 1 line items · $50M tagged
Specific dollar amounts in this bill that flow to identifiable companies or programs — the actual cash trail.
$50M
Sec.1
"Notwithstanding any other provision of the law, amounts authorized to be appropriated or otherwise available for Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act for fiscal year 2024 may not exceed $50,000,000."
→ Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act
Frequently Asked Questions
Did HR.2297 pass?
HR.2297 did not pass and is no longer active. Final stage: COMMITTEE.
What does HR.2297 do?
This bill places a $50 million cap on the total funds that can be made available for the 'Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act' for fiscal year 2024. It overrides any other laws that might authorize or provide more money for this specific account.
Who sponsored HR.2297?
HR.2297 was sponsored by Andy Biggs (R-Arizona).
How much money does HR.2297 spend?
HR.2297 contains $50M in identified line-item carveouts to specific programs and companies, across 1 earmarks.
Full Bill Text
118 HR 2297 IH: To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act for fiscal year 2024. U.S. House of Representatives 2023-03-29 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 118th CONGRESS 1st Session H. R. 2297 IN THE HOUSE OF REPRESENTATIVES March 29, 2023 Mr. Biggs (for himself, Mr. Rosendale , Mr. Gaetz , Mr. Good of Virginia , Mr. Roy , and Mr. Crane ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act for fiscal year 2024. 1. Limitation on availability of funds for Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act for fiscal year 2024 Notwithstanding any other provision of the law, amounts authorized to be appropriated or otherwise available for Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act for fiscal year 2024 may not exceed $50,000,000.
Loading intelligence layer…